NEW YORK – Meridian Bioscience reported on Friday that its fiscal first quarter revenues decreased 8 percent year over year partially due to lower contract pricing for certain gastrointestinal products.
For the three months ended Dec. 31, 2019 the firm reported revenues of $47.4 million, down from $51.5 million a year ago. Meridian missed the average Wall Street estimate of $48.7 million.